findmyKOL

Azeez Farooki, MD

Basic profile

Memorial Sloan Kettering Cancer Center

ORCIDNPI
RegionNew York, NY · NortheastSpecialtyEndocrinology, Diabetes & MetabolismFocusEndocrinology/Metabolic
ActivityNot yet indexedfindmyKOL typefindmyKOL type: our influence ranking, shown when you reveal the full profileLatest publicationSee ScholarshipOnline presenceNot yet checkedPayments2021 onwardNIH fundingNot yet indexedWhy? →

Azeez Farooki is an Endocrinology/Metabolic physician affiliated with Memorial Sloan Kettering Cancer Center. OpenAlex indexes 102 publications with 4,253 citations (h-index 28).

Overview

Scholarship

indexed output and impact (OpenAlex)
102publications

Distinct works indexed by OpenAlex, matched via ORCID.

4,253citations

Total citations across indexed works.

28h-index

Hirsch index, productivity × impact (OpenAlex).

Clinical & industry

trials, payments and federal funding
8companies · 2021 onward

Companies reporting payments to CMS. Facts, not judgments.

View payments

Industry payments

8 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:

8 companies with payments on record in CMS Open Payments (2021 onward), matched to this physician's NPI. The itemized breakdown by company, amount and year is part of the full profile. Why? →

Medicare prescribing footprint (2023)

The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.

  • Metabolism & gastrointestinal

    52.6%
    Insulin Analog13.3%
    Humalog Kwikpen U-10030%Lantus Solostar30%Novolog Flexpen19%Tresiba Flextouch U-1009%Toujeo Solostar7%Basaglar Kwikpen U-1006%
    Part D<11 patients
    Biguanide (metformin)11.1%
    Metformin Hcl67%Metformin Hcl Er34%
    Part D39 patients

    + 7 more classes in this area

  • Cardiovascular

    22.1%
    Statin12.3%
    Atorvastatin Calcium58%Rosuvastatin Calcium42%
    Part D33 patients
    Cholesterol absorption inhibitor2.1%
    Ezetimibe100%
    Part D<11 patients

    + 6 more classes in this area

  • Hormonal (systemic)

    19.5%
    l-Thyroxine11.9%
    Levothyroxine Sodium79%Synthroid21%
    Part D45 patients
    Calcium-sensing Receptor Agonist2.2%
    Cinacalcet Hcl100%
    Part D13 patients

    + 4 more classes in this area

Where care is delivered (Part B)0% facility · 100% office

Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.

Similar KOLs

Other experts from the same institution or the same specialty.

A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”